IT firm Cerner invests in Dx maker Claritas Genomics

Boston Children's Hospital spinoff Claritas Genomics, a genetic diagnostic testing company, attracted an investment from IT specialist Cerner, and the two will collaborate to develop a computing infrastructure designed to smooth the diagnostic process from start to finish. Cerner's Millennium Helix integration software helps to order the genomic sequencing, interpret results and incorporate them into a patient's health record, according to a report from Modern Healthcare. The partnership is another example of a growing trend in which IT and diagnostics companies are joining forces for an integrated approach to product development. "Cerner has long focused on the power of genomics and its impact to clinical processes, and this relationship will help advance the field and define a meaningful narrative in personalized medicine between the realms of research, diagnostics and clinical practice," Cerner Senior Vice President Dick Flanigan said in a statement. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.